Candidaemia, also known as invasive candidiasis, is a serious fungal infection caused by a type of yeast called Candida. Candida is commonly found in the human body, but it can cause infection if it enters the bloodstream or other organs. Candidaemia typically occurs in people with weakened immune systems, such as those undergoing chemotherapy, organ transplantation, or with HIV/AIDS. It can also occur in people who have undergone surgery or have had a central venous catheter inserted.
Symptoms of candidaemia include fever, chills, and low blood pressure, and it can lead to severe complications such as sepsis and organ failure if left untreated. Diagnosis usually involves blood tests to detect the presence of Candida in the bloodstream. Treatment for candidaemia typically involves antifungal medications, such as echinocandins, which work by inhibiting the growth of the fungal cell wall. Early diagnosis and treatment are important in preventing the spread of the infection and improving outcomes for affected individuals.
Caspofungin is a type of echinocandin that is used to treat invasive fungal infections and is generally well-tolerated. However, there are also some disadvantages to caspofungin. It is typically administered intravenously, which may require hospitalization or frequent clinic visits. It may also interact with other medications, and it can cause side effects such as fever, chills, and rash.
In a clinical trial, researchers compared the effectiveness and safety of once weekly rezafungin, a new type of echinocandin, with intravenous caspofungin. They conducted a study with 199 patients who had candidaemia or invasive candidiasis. These patients were randomly assigned to receive either rezafungin or caspofungin for up to four weeks.
The results of the study showed that both medications were equally effective in treating the infection and preventing death. In at least 5 % of the participants in both groups, the most common ones were fever, low potassium, pneumonia, septic shock, and anemia. Over half of the patients in each group experienced serious side effects.
Overall, the study provides important information for doctors who are treating patients with these types of infections. Rezafungin may be more convenient for patients to use, as it only needs to be given once a week. However, further research is needed to evaluate the safety and effectiveness of rezafungin in the initial days of treatment.
ClinicalTrials.gov NCT03667690, Dec-13-22